A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec Docetaxel in Patients With Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Acronyms NAPOLY
- Sponsors Cristal Therapeutics
- 18 Jul 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 18 Jul 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 29 Apr 2016 According to Cristal Therapeutics media release, company has initiated this trial in July 2015.